Pediatric ependymoma: Biological perspectives

Molecular Cancer Research

Volumn 7, Issue 6, 2009, Pages 765-786

  Kilday, John Paul ^a   Rahman, Ruman ^a   Dyer, Sara ^c   Ridley, Lee ^a   Lowe, James ^b   Coyle, Beth ^a   Grundy, Richard ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN P; KI 67 ANTIGEN; METALLOPROTEINASE; NUCLEOLIN; PROTEIN BCL 2; PROTEIN P14; PROTEIN P53; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TENASCIN; VASCULOTROPIN; VITRONECTIN;

CANCER STEM CELL; CELL POPULATION; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MARKER; EPENDYMOMA; GENOMICS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; MEDICAL LITERATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR RESISTANCE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMPARATIVE GENOMIC HYBRIDIZATION; EPENDYMOMA; GENOMICS; HUMANS; INFANT; TUMOR MARKERS, BIOLOGICAL;

EID: 67649612846     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0584     Document Type: Review

References (173)

1. Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 1998;30:319-329, [discussion 29-31]. PubMed doi:10.1002/(SICI)1096-911X(199806)30:6〈319::AID-MPO1〉3.0.CO;2-H. (Pubitemid 28198926)
2. Kulkarni AV, Bouffet E, Drake JM. Ependymal tumors: brain and spinal tumors of childhood. 1st ed. London: Arnold; 2004.
3. Miller RW, Young JL, Jr., Novakovic B. Childhood cancer. Cancer 1995;75[Suppl]:395-405, PubMed doi:10.1002/1097-0142(19950101)75:1+〈395:: AID-CNCR2820751321〉 3.0.CO;2-W.
4. Duffner PK, Krischer JP, Sanford RA, et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 1998;28:215-222, PubMed doi:10.1159/000028654. (Pubitemid 28402001)
5. Grill J, LeDeley MC, Gambarelli D, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001;19:1288-1296, PubMed. (Pubitemid 32202532)
6. Heidemann RLPR, Albright LA, Freeman CR, Rorke LB. Tumors of the central nervous system. 1st ed. Philadelphia: Lippincott-Raven; 1997.
7. Ellison DW. Non-astrocytic gliomas:Neuropathology. London: Mosby; 1998.
8. Wiestler OD, Schiffer D, Coons SW, Prayson RA, Rosenblum MK. Ependymoma: Pathology and genetics of tumors of the central nervous system. Lyon: IARC; 2000.
9. Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 2005;75:287-299, PubMed doi:10.1007/s11060-005-6753-9. (Pubitemid 43019484)
10. Aktug T, Hakguder G, Sarioglu S, Akgur FM, Olguner M, Pabuccuoglu U. Sacrococcygeal extraspinal ependymomas: the role of coccygectomy. J Pediatr Surg 2000;35:515-518, PubMed doi:10.1016/S0022-3468(00)90228-8. (Pubitemid 30131625)
11. Hirahara F, Yamanaka M, Miyagia E, et al. Pure ovarian ependymoma: report of a case treated with surgery, chemotherapy, irradiation and hyperthermotherapy. Eur J Obstet Gynecol Reprod Biol 1997;75:221-223, PubMed doi:10.1016/S0301-2115(97)00134-6. (Pubitemid 28008052)
12. Zacharoulis S, Levy A, Chi SN, et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007;49:34-40, PubMed doi:10.1002/pbc.20935. (Pubitemid 46847065)
13. Paulino AC, Wen BC, Buatti JM, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol 2002;25:117-122, PubMed doi:10.1097/00000421-200204000-00003. (Pubitemid 34293061)
14. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol 1997;7:807-822, PubMed doi:10.1111/j.1750-3639.1997.tb01066.x. (Pubitemid 27234254)
15. Tabori U, Vukovic B, Zielenska M, et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia 2006;8:136-142, PubMed doi:10.1593/neo.05715.
16. Horn B, Heideman R, Geyer R, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol 1999;21:203-211, PubMed doi:10.1097/00043426-199905000- 00008. (Pubitemid 30306031)
17. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998;88:695-703, PubMed. (Pubitemid 28145213)
18. Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ. The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors. Mod Pathol 2008;21:165-177, PubMed. (Pubitemid 351172168)
19. Akyuz C, Emir S, Akalan N, Soylemezoglu F, Kutluk T, Buyukpamukcu M. Intracranial ependymomas in childhood-a retrospective review of sixty-two children. Acta Oncol 2000;39:97-100, PubMed doi:10.1080/028418600431049. (Pubitemid 30216623)
20. Goldwein JW, Leahy JM, Packer RJ, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 1990;19:1497-1502, PubMed.
21. Sowar K, Straessle J, Donson AM, Handler M, Foreman NK. Predicting which children are at risk for ependymoma relapse. J Neurooncol 2006;78:41-46, PubMed doi:10.1007/s11060-005-9072-2. (Pubitemid 43786656)
22. Perilongo G, Massimino M, Sotti G, et al. Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neurooncology Group. Med Pediatr Oncol 1997;29:79-85, PubMed doi:10.1002/(SICI)1096-911X(199708)29:2〈79::AID-MPO3〉3.0.CO;2-O. (Pubitemid 27242225)
23. Sala F, Talacchi A, Mazza C, Prisco R, Ghimenton C, Bricolo A. Prognostic factors in childhood intracranial ependymomas: the role of age and tumor location. Pediatr Neurosurg 1998;28:135-142, PubMed doi:10.1159/000028637. (Pubitemid 28385584)
24. Sutton LN, Goldwein J, Perilongo G, et al. Prognostic factors in childhood ependymomas. Pediatr Neurosurg 1990;16:57-65, PubMed doi:10.1159/000120509.
25. Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007;8:696-705, PubMed doi:10.1016/S1470- 2045(07)70208-5. (Pubitemid 47189085)
26. Rousseau P, Habrand JL, Sarrazin D, et al. Treatment of intracranial ependymomas of children: review of a 15-year experience. Int J Radiat Oncol Biol Phys 1994;28:381-386, PubMed. (Pubitemid 24020522)
27. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer 2004;100:1230-1237, PubMed doi:10.1002/cncr.20075. (Pubitemid 38325952)
28. Massimino M, Gandola L, Giangaspero F, et al. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys 2004;58:1336-1345, PubMed doi:10.1016/j.ijrobp.2003.08.030. (Pubitemid 38438292)
29. Merchant TE, Mulhern RK, Krasin MJ, et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004;22:3156-3162, PubMed doi:10.1200/JCO.2004.11.142. (Pubitemid 41103730)
30. Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M. Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol 2002;56:87-94, PubMed doi:10.1023/A: 1014442106111. (Pubitemid 34256622)
31. Rickert CH, Paulus W. Prognosis-related histomorphological and immunohistochemical markers in central nervous system tumors of childhood and adolescence. Acta Neuropathol 2005;109:69-92, PubMed doi:10.1007/s00401-004- 0959-3. (Pubitemid 40287791)
32. Ridley L, Rahman R, Brundler MA, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro-oncol 2008;10:675-689, PubMed doi:10.1215/15228517-2008-036.
33. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer 2007;96:6-10, PubMed doi:10.1038/sj.bjc.6603519. (Pubitemid 46094631)
34. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005;8:323-335, PubMed doi:10.1016/j.ccr.2005.09.001. (Pubitemid 41443417)
35. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 2002;58:255-270, PubMed doi:10.1023/A:1016222202230. (Pubitemid 34830636)
36. Ritter AM, Hess KR, McLendon RE, Langford LA. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol 1998;40:51-57, PubMed doi:10.1023/A:1006082622699.
37. Agamanolis DP, Malone JM. Chromosomal abnormalities in 47 pediatric brain tumors. Cancer Genet Cytogenet 1995;81:125-134, PubMed doi:10.1016/0165- 4608(94)00123-S.
38. Bhattacharjee MB, Armstrong DD, Vogel H, Cooley LD. Cytogenetic analysis of 120 primary pediatric brain tumors and literature review. Cancer Genet Cytogenet 1997;97:39-53, PubMed doi:10.1016/S0165-4608(96)00330-5. (Pubitemid 27318476)
39. Bigner SH, McLendon RE, Fuchs H, McKeever PE, Friedman HS. Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet 1997;97:125-134, PubMed doi:10.1016/S0165-4608(96)00404-9. (Pubitemid 27362507)
40. Debiec-Rychter M, Biernat W, Zakrzewski K, Krul W, Liberski PP. Loss of chromosome 22 and proliferative potential in ependymomas. Folia Neuropathol 2003;41:191-195, PubMed. (Pubitemid 38185916)
41. Griffin CA, Long PP, Carson BS, Brem H. Chromosome abnormalities in low-grade central nervous system tumors. Cancer Genet Cytogenet 1992;60:67-73, PubMed doi:10.1016/0165-4608(92)90235-Z.
42. Jenkins RB, Kimmel DW, Moertel CA, et al. A cytogenetic study of 53 human gliomas. Cancer Genet Cytogenet 1989;39:253-279, PubMed doi:10.1016/0165- 4608(89)90192-1. (Pubitemid 19214168)
43. Kramer DL, Parmiter AH, Rorke LB, Sutton LN, Biegel JA. Molecular cytogenetic studies of pediatric ependymomas. J Neurooncol 1998;37:25-33, PubMed doi:10.1023/A:1005925613992. (Pubitemid 28073572)
44. Mazewski C, Soukup S, Ballard E, Gotwals B, Lampkin B. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet 1999;113:1-8, PubMed doi:10.1016/S0165-4608(99)00046-1. (Pubitemid 29354085)
45. Neumann E, Kalousek DK, Norman MG, Steinbok P, Cochrane DD, Goddard K. Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet Cytogenet 1993;71:40-49, PubMed doi:10.1016/0165-4608(93)90200-6. (Pubitemid 24032325)
46. Roberts P, Chumas PD, Picton S, Bridges L, Livingstone JH, Sheridan E. A review of the cytogenetics of 58 pediatric brain tumors. Cancer Genet Cytogenet 2001;131:1-12, PubMed doi:10.1016/S0165-4608(01)00483-6. (Pubitemid 33081151)
47. Rogatto SR, Casartelli C, Rainho CA, Barbieri-Neto J. Chromosomes in the genesis and progression of ependymomas. Cancer Genet Cytogenet 1993;69:146-152, PubMed doi:10.1016/0165-4608(93)90093-2. (Pubitemid 23313856)
48. Sainati L, Bolcato S, Montaldi A, et al. Cytogenetics of pediatric central nervous system tumors. Cancer Genet Cytogenet 1996;91:13-27, PubMed doi:10.1016/S0165-4608(96)00036-2. (Pubitemid 26398359)
49. Sawyer JR, Sammartino G, Husain M, Boop FA, Chadduck WM. Chromosome aberrations in four ependymomas. Cancer Genet Cytogenet 1994;74:132-138, PubMed doi:10.1016/0165-4608(94)90011-6. (Pubitemid 24208881)
50. Stratton MR, Darling J, Lantos PL, Cooper CS, Reeves BR. Cytogenetic abnormalities in human ependymomas. Int J Cancer 1989;44:579-581, PubMed doi:10.1002/ijc.2910440403. (Pubitemid 19258726)
51. Thiel G, Losanowa T, Kintzel D, et al. Karyotypes in 90 human gliomas. Cancer Genet Cytogenet 1992;58:109-120, PubMed doi:10.1016/0165-4608(92)90095-P.
52. Urioste M, Martinez-Ramirez A, Cigudosa JC, et al. Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. Cancer Genet Cytogenet 2002;138:107-110, PubMed doi:10.1016/S0165- 4608(01)00532-5. (Pubitemid 36024172)
53. Vagner-Capodano AM, Gentet JC, Gambarelli D, et al. Cytogenetic studies in 45 pediatric brain tumors. Pediatr Hematol Oncol 1992;9:223-235, PubMed doi:10.3109/08880019209016590.
54. Weremowicz S, Kupsky WJ, Morton CC, Fletcher JA. Cytogenetic evidence for a chromosome 22 tumor suppressor gene in ependymoma. Cancer Genet Cytogenet 1992;61:193-196, PubMed doi:10.1016/0165-4608(92)90085-M.
55. Wernicke C, Thiel G, Lozanova T, et al. Involvement of chromosome 22 in ependymomas. Cancer Genet Cytogenet 1995;79:173-176, PubMed doi:10.1016/0165- 4608(94)00148-5.
56. Dal Cin P, Van den Berghe H, Buonamici L, Losi L, Roncaroli F, Calbucci F. Cytogenetic investigation in subependymoma. Cancer Genet Cytogenet 1999;108:84, PubMed doi:10.1016/S0165-4608(98)00126-5. (Pubitemid 29019091)
57. Thangavelu M, Turina J, Tomita T, Chou PM. Clonal cytogenetic abnormalities in pediatric brain tumors: cytogenetic analysis and clinical correlation. Pediatr Neurosurg 1998;28:15-20, PubMed doi:10.1159/000028612. (Pubitemid 28354374)
58. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002;86:929-939, PubMed doi:10.1038/sj.bjc.6600180. (Pubitemid 34271030)
59. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002;161:2133-2141, PubMed. (Pubitemid 35434859)
60. Granzow M, Popp S, Weber S, et al. Isochromosome 1q as an early genetic event in a child with intracranial ependymoma characterized by molecular cytogenetics. Cancer Genet Cytogenet 2001;130:79-83, PubMed doi:10.1016/S0165- 4608(01)00465-4. (Pubitemid 32979171)
61. Grill J, Avet-Loiseau H, Lellouch-Tubiana A, et al. Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet 2002;136:121-125, PubMed doi:10.1016/S0165-4608(02)00516-2. (Pubitemid 35292023)
62. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 2001;158:1137-1143, PubMed. (Pubitemid 32221806)
63. Jeuken JW, Sprenger SH, Gilhuis J, Teepen HL, Grotenhuis AJ, Wesseling P. Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol 2002;197:238-244, PubMed doi:10.1002/path.1086. (Pubitemid 34567612)
64. Pezzolo A, Capra V, Raso A, et al. Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. Cancer Lett 2008;261:235-243, PubMed.
65. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-1397, PubMed doi:10.1200/JCO.20.5.1389.
66. Rickert CH, Korshunov A, Paulus W. Chromosomal imbalances in clear cell ependymomas. Mod Pathol 2006;19:958-962, PubMed doi:10.1038/modpathol.3800614. (Pubitemid 43910475)
67. Scheil S, Bruderlein S, Eicker M, et al. Low frequency of chromosomal imbalances in anaplastic ependymomas as detected by comparative genomic hybridization. Brain Pathol 2001;11:133-143, PubMed. (Pubitemid 32198841)
68. Shlomit R, Ayala AG, Michal D, et al. Gains and losses of DNA sequences in childhood brain tumors analyzed by comparative genomic hybridization. Cancer Genet Cytogenet 2000;121:67-72, PubMed doi:10.1016/S0165-4608(00)00218-1. (Pubitemid 30665744)
69. Ward S, Harding B, Wilkins P, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. Genes Chromosomes Cancer 2001;32:59-66, PubMed doi:10.1002/gcc.1167. (Pubitemid 32737785)
70. Zheng PP, Pang JC, Hui AB, Ng HK. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet Cytogenet 2000;122:18-25, PubMed doi:10.1016/S0165-4608(00)00265-X. (Pubitemid 30833969)
71. Reardon DA, Entrekin RE, Sublett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 1999;24:230-237, PubMed doi:10.1002/(SICI)1098-2264(199903)24:3〈230::AID-GCC8〉3.0.CO;2-C. (Pubitemid 29070162)
72. Isola JJ, Kallioniemi OP, Chu LW, et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995;147:905-911, PubMed.
73. Rooney PH, Boonsong A, McKay JA, et al. Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer 2001;85:1492-1498, PubMed doi:10.1054/bjoc.2001.2095. (Pubitemid 34001579)
74. Gilhuis HJ, van der Laak J, Wesseling P, et al. Inverse correlation between genetic aberrations and malignancy grade in ependymal tumors: a paradox? J Neurooncol 2004;66:111-116, PubMed doi:10.1023/B:NEON.0000013493.31107.20. (Pubitemid 38258365)
75. Chessels JM, Swansbury GJ, Reeves B, Bailey CC, Richards SM. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997;99:93-100, PubMed doi:10.1046/j.1365-2141.1997.3493163.x.
76. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006;24:5223-5233, PubMed doi:10.1200/JCO.2006.06.3701. (Pubitemid 46631366)
77. Korshunov A, Neben K, Wrobel G, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol 2003;163:1721-1727, PubMed. (Pubitemid 37310002)
78. Rajaram V, Gutmann DH, Prasad SK, Mansur DB, Perry A. Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol 2005;18:991-997, PubMed doi:10.1038/modpathol.3800390. (Pubitemid 41059962)
79. Rousseau E, Ruchoux MM, Scaravilli F, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol 2003;29:574-583, PubMed doi:10.1046/j.0305-1846.2003.00505.x.
80. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-823, PubMed doi:10.1073/pnas.68.4.820.
81. Scotting PJ, Walker DA, Perilongo G. Childhood solid tumours: a developmental disorder. Nat Rev Cancer 2005;5:481-488, PubMed doi:10.1038/nrc1633. (Pubitemid 40791490)
82. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999;155:627-632, PubMed. (Pubitemid 29370412)
83. Lukashova-v Zangen I, Kneitz S, Monoranu CM, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 2007;113:325-337, PubMed doi:10.1007/s00401- 006-0190-5. (Pubitemid 46443567)
84. Lamszus K, Lachenmayer L, Heinemann U, et al. Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. Int J Cancer 2001;91:803-808, PubMed doi:10.1002/1097-0215(200002)9999:9999〈::AID- IJC1134〉3.0.CO;2-P. (Pubitemid 32178648)
85. Singh PK, Gutmann DH, Fuller CE, Newsham IF, Perry A. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol 2002;15:526-531, PubMed doi:10.1038/ modpathol.3880558. (Pubitemid 34521401)
86. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006;12:2070-2079, PubMed doi:10.1158/1078-0432.CCR-05-2363.
87. Waha A, Koch A, Hartmann W, et al. Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 2004;110:542-549, PubMed doi:10.1002/ijc.20165. (Pubitemid 38658019)
88. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988, PubMed doi:10.1073/pnas.0530291100. (Pubitemid 36418143)
89. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737, PubMed doi:10.1038/nm0797-730. (Pubitemid 27298715)
90. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648, PubMed doi:10.1038/367645a0. (Pubitemid 24067706)
91. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110, PubMed doi:10.1038/nature05372. (Pubitemid 46067310)
92. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115, PubMed doi:10.1038/nature05384. (Pubitemid 46067311)
93. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-5828, PubMed. (Pubitemid 37187480)
94. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401, PubMed doi:10.1038/ nature03128. (Pubitemid 39551674)
95. Spassky N, Merkle FT, Flames N, Tramontin AD, Garcia-Verdugo JM, Alvarez-Buylla A. Adult ependymal cells are postmitotic and are derived from radial glial cells during embryogenesis. J Neurosci 2005;25:10-18, PubMed doi:10.1523/JNEUROSCI.1108-04.2005. (Pubitemid 40110761)
96. Hartfuss E, Galli R, Heins N, Gotz M. Characterization of CNS precursor subtypes and radial glia. Dev Biol 2001;229:15-30, PubMed doi:10.1006/dbio.2000. 9962. (Pubitemid 32061711)
97. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Pro c Natl Acad Sci U S A 2000;97:14720-14725, PubMed doi:10.1073/pnas.97.26.14720. (Pubitemid 32016642)
98. Kriegstein AR, Gotz M. Radial glia diversity: a matter of cell fate. Glia 2003;43:37-43, PubMed doi:10.1002/glia.10250. (Pubitemid 36781695)
99. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598, PubMed doi:10.1038/nature07567.
100. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006;6:425-436, PubMed doi:10.1038/nrc1889.
101. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109, PubMed doi:10.1007/s00401-007-0243-4.
102. Schiffer D, Chio A, Cravioto H, et al. Ependymoma: internal correlations among pathological signs: the anaplastic variant. Neurosurgery 1991;29:206-210, PubMed doi:10.1097/00006123-199108000-00006.
103. Ellison DKM, Figarella-Branger D, Giangaspero F, et al. Grundy R Histopathological grading of intracranial pediatric ependymomas. International Symposium of Pediatric Neuro-Oncology. Chicago; 2008.
104. Altura RA, Olshefski RS, Jiang Y, Boue DR. Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer 2003;89:1743-1749, PubMed doi:10.1038/sj.bjc.6601334. (Pubitemid 37464149)
105. Asai A, Hoshino T, Edwards MS, Davis RL. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index. Childs Nerv Syst 1992;8:273-278, PubMed doi:10.1007/BF00300795.
106. Athanasiou A, Perunovic B, Quilty RD, Gorgoulis VG, Kittas C, Love S. Expression of mos in ependymal gliomas. Am J Clin Pathol 2003;120:699-705, PubMed doi:10.1309/DL2TLDJG7JB1BQ72. (Pubitemid 37339676)
107. Bennetto L, Foreman N, Harding B, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol 1998;24:434-440, PubMed doi:10.1046/j.1365-2990.1998.00143.x. (Pubitemid 29002274)
108. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al. Prognostic factors in intracranial ependymomas in children. J Neurosurg 2000;93:605-613, PubMed doi:10.3171/jns.2000.93.4.0605. (Pubitemid 32799294)
109. Figarella-Branger D, Gambarelli D, Dollo C, et al. Infratentorial ependymomas of childhood. Correlation between histological features, immunohistological phenotype, silver nucleolar organizer region staining values and post-operative survival in 16 cases. Acta Neuropathol 1991;82:208-216, PubMed doi:10.1007/BF00294447.
110. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002;8:3054-3064, PubMed. (Pubitemid 35155014)
111. Ho DM, Hsu CY, Wong TT, Chiang H. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neurooncol 2001;54:77-85, PubMed doi:10.1023/A:1012590505236. (Pubitemid 33089263)
112. Karakoula K, Suarez-Merino B, Ward S, et al. Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13. Genes Chromosomes Cancer 2008;47:1005-1022
113. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for intracranial ependymoma recurrence. Ananalysis of 88 cases. J Neurol Sci 2000;177:72-82, PubMed doi:10.1016/S0022-510X(00)00347-6. (Pubitemid 30674504)
114. Korshunov A, Golanov A, Timirgaz V. p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases. Acta Neuropathol 2001;102:271-277, PubMed.
115. Korshunov A, Sycheva R, Timirgaz V, Golanov A. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 1999;45:219-227, PubMed doi:10.1023/A: 1006369829576. (Pubitemid 30315739)
116. Monoranu CM, Huang B, Zangen IL, et al. Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas. Cancer Genet Cytogenet 2008;182:18-26, PubMed doi:10.1016/j.cancergencyto.2007.12.008. (Pubitemid 351323960)
117. Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 1997;93:109-117, PubMed doi:10.1007/s004010050591. (Pubitemid 27060902)
118. Prayson RA. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases. Am J Clin Pathol 1998;110:629-634, PubMed. (Pubitemid 28491968)
119. Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol 2005;124:543-549, PubMed doi:10.1309/PP2G5GAAFKV82DTG. (Pubitemid 41395635)
120. Preusser M, Wolfsberger S, Haberler C, et al. Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol 2005;109:211-216, PubMed doi: 10.1007/s00401-004-0938-8. (Pubitemid 40468391)
121. Rajaram V, Leuthardt EC, Singh PK, et al. 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. Mod Pathol 2004;17:9-14, PubMed doi:10.1038/modpathol.3800029.
122. Rezai AR, Woo HH, Lee M, Cohen H, Zagzag D, Epstein FJ. Disseminated ependymomas of the central nervous system. J Neurosurg 1996;85:618-624, PubMed. (Pubitemid 26315195)
123. Schiffer D, Chio A, Giordana MT, Pezzulo T, Vigliani MC. Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathol 1993;85:495-502, PubMed doi:10.1007/BF00230488. (Pubitemid 23180411)
124. Shuangshoti S, Rushing EJ, Mena H, Olsen C, Sandberg GD. Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer 2005;103:2598-2605, PubMed doi:10.1002/cncr.21111. (Pubitemid 40800540)
125. Snuderl M, Chi SN, De Santis SM, et al. Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol 2008;67:911-920, PubMed doi:10.1097/NEN.0b013e318184f413.
126. Tabori U, Ma J, Carter M, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 2006;24:1522-1528, PubMed doi:10.1200/JCO.2005.04.2127. (Pubitemid 46638773)
127. Verstegen MJ, Leenstra DT, Ijlst-Keizers H, Bosch DA. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis. J Neurooncol 2002;56:21-28, PubMed doi:10.1023/A:1014471714058. (Pubitemid 34256614)
128. Zamecnik J, Snuderl M, Eckschlager T, et al. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 2003;16:980-991, PubMed doi:10.1097/01.MP. 0000087420.34166.B6. (Pubitemid 37280813)
129. Zamecnik J, Vargova L, Homola A, Kodet R, Sykova E. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol Appl Neurobiol 2004;30:338-350, PubMed doi:10.1046/j.0305-1846.2003.00541.x. (Pubitemid 39120295)
130. Cong YS, Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 2000;275:35665-35668, PubMed doi:10.1074/jbc.C000637200. (Pubitemid 30841095)
131. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-1929, PubMed.
132. Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases mutation rate and genomic instability. Cell 2001;106:275-286, PubMed doi:10.1016/S0092-8674(01)00457-3. (Pubitemid 32772612)
133. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007;11:461-469, PubMed doi:10.1016/j.ccr. 2007.02.026. (Pubitemid 46670077)
134. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460, PubMed doi:10.1038/345458a0. (Pubitemid 20178256)
135. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791, PubMed doi:10.1016/S0959-8049(97)00062-2. (Pubitemid 127704664)
136. Wu YL, Dudognon C, Nguyen E, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 2006;119:2797-2806, PubMed doi:10.1242/jcs.03001. (Pubitemid 44184016)
137. Didiano D, Shalaby T, Lang D, Grotzer MA. Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-oncol 2004;6:1-8, PubMed doi:10.1215/S1152851703000176. (Pubitemid 38139632)
138. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836-838, PubMed doi:10.1016/S0140-6736(03)12681-5. (Pubitemid 36331849)
139. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715, PubMed. (Pubitemid 14035254)
140. Rushing EJ, Brown DF, Hladik CL, Risser RC, Mickey BE, White CL III. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype. Mod Pathol 1998;11:464-470, PubMed. (Pubitemid 28224449)
141. Suri VS, Tatke M, Singh D, Sharma A. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype. Indian J Cancer 2004;41:66-71, PubMed. (Pubitemid 39164005)
142. Suzuki S, Oka H, Kawano N, Tanaka S, Utsuki S, Fujii K. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas. Brain Tumor Pathol 2001;18:151-154, PubMed doi:10.1007/BF02479429.
143. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001;158:393-398, PubMed. (Pubitemid 32158602)
144. Hirai M, Yoshida S, Kashiwagi H, et al. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment. Genes Chromosomes Cancer 1999;25:261-269, PubMed doi:10.1002/(SICI)1098-2264(199907)25: 3〈261::AID-GCC8〉3.0.CO;2-#. (Pubitemid 29266695)
145. Ozaki T, Paulussen M, Poremba C, et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 2001;32:164-171, PubMed doi:10.1002/gcc.1178.
146. Almeida A, Zhu XX, Vogt N, et al. GAC1, a new member of the leucinerich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas. Oncogene 1998;16:2997-3002, PubMed doi: 10.1038/sj.onc. 1201828. (Pubitemid 28297721)
147. Rand V, Prebble E, Ridley L, et al. Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. Br J Cancer 2008;99:1136-1143, PubMed doi:10.1038/sj.bjc.6604651.
148. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro-oncol 2005;7:20-31, PubMed doi:10.1215/S1152851704000596. (Pubitemid 40310190)
149. Hulsebos TJ, Oskam NT, Bijleveld EH, et al. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer 1999;81:1150-1154, PubMed doi:10.1038/sj.bjc.6690822.
150. Yokota T, Tachizawa T, Fukino K, et al. A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor. J Hum Genet 2003;48:598-602, PubMed doi:10.1007/s10038-003-0078-3. (Pubitemid 38017657)
151. Ammerlaan AC, de Bustos C, Ararou A, et al. Localization of a putative low-penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling-path genomic microarray. Genes Chromosomes Cancer 2005;43:329-338, PubMed doi:10.1002/gcc.20207. (Pubitemid 40946468)
152. Huang B, Starostik P, Kuhl J, Tonn JC, Roggendorf W. Loss of heterozygosity on chromosome 22 in human ependymomas. Acta Neuropathol 2002;103:415-420, PubMed doi:10.1007/s00401-001-0479-3. (Pubitemid 36097037)
153. Kraus JA, de Millas W, Sorensen N, et al. Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. Acta Neuropathol 2001;102:69-74, PubMed. (Pubitemid 32734267)
154. Seven et N, Lellouch-Tubiana A, Schofield D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 1999;8:2359-2368, PubMed doi:10.1093/hmg/8.13.2359.
155. Michalowski MB, de Fraipont F, Michelland S, et al. Methylation of RASS-F1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet 2006;166:74-81, PubMed doi:10.1016/j.cancergencyto.2005.09.004.
156. Huang B, Starostik P, Schraut H, Krauss J, Sorensen N, Roggendorf W. Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol 2003;106:357-362, PubMed doi:10.1007/s00401-003-0739-5. (Pubitemid 37265315)
157. Rousseau-Merck M, Versteege I, Zattara-Cannoni H, et al. Fluorescence in situ hybridization determination of 22q12-q13 deletion in two intracerebral ependymomas. Cancer Genet Cytogenet 2000;121:223-227, PubMed doi:10.1016/S0165-4608(00)00262-4. (Pubitemid 30785807)
158. Garwood J, Garcion E, Dobbertin A, et al. The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor. Eur J Neurosci 2004;20:2524-2540, PubMed doi:10.1111/j.1460-9568.2004.03727.x. (Pubitemid 39573769)
159. Fink KL, Rushing EJ, Schold SC, Jr., Nisen PD. Infrequency of p53 gene mutations in ependymomas. J Neurooncol 1996;27:111-115, PubMed doi:10.1007/BF00177473. (Pubitemid 26052645)
160. Gaspar N, Grill J, Geoerger B, Lellouch-Tubiana A, Michalowski MB, Vassal G.p53 Pathway dysfunction in primary childhood ependymomas. Pediatr Blood Cancer 2006;46:604-613, PubMed doi:10.1002/pbc.20532.
161. Tong CY, Ng HK, Pang JC, Hui AB, Ko HC, Lee JC. Molecular genetic analysis of non-astrocytic gliomas. Histopathology 1999;34:331-341, PubMed doi:10.1046/j.1365-2559.1999.00603.x. (Pubitemid 29229988)
162. von Haken MS, White EC, Daneshvar-Shyesther L, et al. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer 1996;17:37-44, PubMed doi:10.1002/(SICI)1098-2264(199609)17:〈37::AIDGCC6〉3.0.CO;2-3. (Pubitemid 26327933)
163. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444: 756-760, PubMed doi:10.1038/nature05236. (Pubitemid 44949604)
164. Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007;67: 8980-8984, PubMed doi:10.1158/0008-5472. CAN-07-0895. (Pubitemid 47535877)
165. Buccoliero AM, Castiglione F, Rossi Degl'Innocenti D, et al. O6-Methylguanine- DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry. J Chemother 2008;20:263-268, PubMed.
166. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284, PubMed doi:10.1038/nrc1590. (Pubitemid 40488633)
167. Kim M, Morshead CM. Distinct populations of forebrain neural stem and progenitor cells can be isolated using side-population analysis. J Neurosci 2003;23:10703-10709, PubMed. (Pubitemid 37485284)
168. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67, PubMed doi:10.1186/1476-4598-5-67. (Pubitemid 44942887)
169. Onilude OE, Lusher ME, Lindsey JC, Pearson AD, Ellison DW, Clifford SC. APC and CTNNB1 mutations are rare in sporadic ependymomas. Cancer Genet Cytogenet 2006;168:158-161, PubMed doi:10.1016/j.cancergencyto.2006.02.019.
170. Hitoshi S, Alexson T, Tropepe V, et al. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev 2002;16:846-858, PubMed doi:10.1101/gad.975202. (Pubitemid 34280108)
171. Nyfeler Y, Kirch RD, Mantei N, et al. Jagged1 signals in the postnatal subventricular zone are required for neural stem cell self-renewal. EMBO J 2005;24:3504-3515, PubMed doi:10.1038/sj.emboj.7600816. (Pubitemid 41486787)
172. Gaiano N, Nye JS, Fishell G. Radial glial identity is promoted by Notch1 signaling in the murine forebrain. Neuron 2000;26:395-404, PubMed doi:10.1016/S0896-6273(00)81172-1. (Pubitemid 30953932)
173. Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res 2005;65:4975-4978, PubMed doi:10.1158/0008-5472.CAN-05-0481. (Pubitemid 40827300)